Online citations, reference lists, and bibliographies.

MicroRNA Array Analysis Finds Elevated Serum MiR-1290 Accurately Distinguishes Patients With Low-Stage Pancreatic Cancer From Healthy And Disease Controls

A. Li, J. Yu, H. Kim, C. Wolfgang, M. Canto, R. Hruban, M. Goggins
Published 2013 · Medicine
Cite This
Download PDF
Analyze on Scholarcy
Share
Purpose: Our goal was to identify circulating micro RNA (miRNA) levels that could distinguish patients with low-stage pancreatic cancer from healthy and disease controls. Experimental Design: We measured 735 miRNAs in pancreatic cancer case and control sera by QRTPCR using TaqMan MicroRNA Arrays. After array analysis, we selected 18 miRNA candidates for validation in an independent set of cases and control samples. Results: Of the significantly elevated circulating miRNAs in patients with pancreatic cancer compared with controls, miR-1290 had the best diagnostic performance: receiver operating characteristic (ROC) analysis on miR-1290 serum level yielded curve areas (AUC) of 0.96 [95% confidence interval (CI), 0.91–1.00], 0.81 (0.71–0.91), and 0.80 (0.67–0.93), for subjects with pancreatic cancer (n = 41) relative to healthy controls (n = 19), subjects with chronic pancreatitis (n = 35), and pancreatic neuroendocrine tumors (n = 18), respectively. Serum miR-1290 levels were also significantly higher than healthy controls among patients with intraductal papillary mucinous neoplasm (IPMN; n = 20; AUC = 0.76, 0.61–0.91). Serum miR-1290 levels distinguished patients with low-stage pancreatic cancer from controls better than CA19-9 levels, and like CA19-9, higher miR-1290 levels predicted poorer outcome among patients undergoing pancreaticoduodenectomy. Greater numbers of miR-1290 transcripts were detected by FISH in primary pancreatic cancer and IPMN than normal pancreatic duct cells. miR-1290 influenced in vitro pancreatic cancer cell proliferation and invasive ability. Several other circulating miRNAs distinguished sera of patients with pancreatic cancer from those of healthy controls with AUCs >0.7, including miR-24, miR-134, miR-146a, miR-378, miR-484, miR-628-3p, and miR-1825. Conclusions: The detection of elevated circulating miR-1290 has the potential to improve the early detection of pancreatic cancer. Clin Cancer Res; 19(13); 3600–10. ©2013 AACR.
This paper references
10.1097/01.MPA.0000335467.08066.A7
MicroRNA miR-155 is a biomarker of early pancreatic neoplasia.
Nils Habbe (2009)
10.1158/1078-0432.CCR-12-0035
miRNA Biomarkers in Cyst Fluid Augment the Diagnosis and Management of Pancreatic Cysts
H. Matthaei (2012)
10.1016/j.cgh.2006.02.005
Screening for early pancreatic neoplasia in high-risk individuals: a prospective controlled study.
M. Canto (2006)
10.1002/ijc.26422
Combination of plasma microRNAs with serum CA19-9 for early detection of pancreatic cancer.
Jian-qiang Liu (2012)
10.1016/j.gassur.2006.08.018
1423 pancreaticoduodenectomies for pancreatic cancer: A single-institution experience
J. Winter (2006)
10.1038/bjc.2011.453
Novel diagnostic value of circulating miR-18a in plasma of patients with pancreatic cancer
R. Morimura (2011)
10.1038/sj.onc.1210228
MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma
A. E. Szafranska (2007)
10.1053/j.gastro.2011.12.042
Presence of somatic mutations in most early-stage pancreatic intraepithelial neoplasia.
M. Kanda (2012)
10.1158/1940-6207.CAPR-09-0094
MicroRNAs in Plasma of Pancreatic Ductal Adenocarcinoma Patients as Novel Blood-Based Biomarkers of Disease
Jin Wang (2009)
10.1136/gut.2008.171611
Five years of prospective screening of high-risk individuals from families with familial pancreatic cancer
Peter Langer (2009)
10.1136/gutjnl-2012-303108
International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer
M. Canto (2012)
10.1038/ajg.2011.65
Feasibility and Yield of Screening in Relatives From Familial Pancreatic Cancer Families
Emmy Ludwig (2011)
10.1158/0008-5472.CAN-09-4227
Pancreatic cancers epigenetically silence SIP1 and hypomethylate and overexpress miR-200a/200b in association with elevated circulating miR-200a and miR-200b levels.
Ang Li (2010)
10.1373/clinchem.2011.172767
Serum microRNA expression profile as a biomarker in the diagnosis and prognosis of pancreatic cancer.
Rui Liu (2012)
Differentially expressed miRNAs in the plasma may provide a molecular signature for aggressive pancreatic cancer.
Shadan Ali (2010)
10.1136/gutjnl-2012-302823
Mutant GNAS detected in duodenal collections of secretin-stimulated pancreatic juice indicates the presence or emergence of pancreatic cysts
M. Kanda (2012)
10.1158/1078-0432.CCR-11-1718
Genome-Wide CpG Island Profiling of Intraductal Papillary Mucinous Neoplasms of the Pancreas
S. Hong (2011)
10.1530/ERC-12-0207
miR-1290 and its potential targets are associated with characteristics of estrogen receptor α-positive breast cancer.
Yumi Endo (2013)
10.1007/s11605-008-0584-x
MicroRNA-21 is Overexpressed in Pancreatic Cancer and a Potential Predictor of Survival
Mary Dillhoff (2008)
10.1158/0008-5472.CAN-05-2664
DNA methylation alterations in the pancreatic juice of patients with suspected pancreatic disease.
H. Matsubayashi (2006)
10.7326/0003-4819-131-4-199908170-00003
Early Diagnosis and Treatment of Pancreatic Dysplasia in Patients with a Family History of Pancreatic Cancer
T. Brentnall (1999)
miR146a suppresses invasion of pancreatic cancer cells
Y Li (2010)
of Potential Conflicts of Interest No potential conflicts of interest were disclosed
10.1159/000231984
Aberrant MicroRNA-155 Expression Is an Early Event in the Multistep Progression of Pancreatic Adenocarcinoma
J. K. Ryu (2010)
10.1001/jama.297.17.1901
MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis.
M. Bloomston (2007)
Clin Cancer Res Clinical Cancer Research
(2013)
Cancer statistics 1423 pancreaticoduodenectomies for pancreatic cancer: A single-institution experience
R Siegel (2006)
10.1158/1078-0432.CCR-11-2347
MicroRNA Alterations of Pancreatic Intraepithelial Neoplasias
J. Yu (2011)
10.1158/1055-9965.EPI-10-0667
Detection of Early-Stage Pancreatic Adenocarcinoma
D. Gold (2010)
10.3322/caac.20138
Cancer statistics, 2012.
Rebecca L Siegel (2012)
10.1158/1078-0432.CCR-10-0248
Serum Biomarker Panels for the Detection of Pancreatic Cancer
R. Brand (2011)
International Consensus Recommendations on the Management of Patients with Increased Risk for Familial Pancreatic Cancer (The Cancer of the Pancreas Screening (CAPS) Consortium Summit)
MI Canto (2013)
10.1038/nprot.2010.62
Rapid in situ codetection of noncoding RNAs and proteins in cells and formalin-fixed paraffin-embedded tissue sections without protease treatment
Mariàngels de Planell-Saguer (2010)
10.1093/nar/gkp482
Imaging individual microRNAs in single mammalian cells in situ
Jing Lu (2009)
10.4161/cbt.8.21.9685
A resource for analysis of microRNA expression and function in pancreatic ductal adenocarcinoma cells
Oliver A. Kent (2009)
10.1093/nar/gkn725
High-throughput stem-loop RT-qPCR miRNA expression profiling using minute amounts of input RNA
P. Mestdagh (2008)
10.1371/journal.pone.0034151
Diagnosis of Pancreatic Ductal Adenocarcinoma and Chronic Pancreatitis by Measurement of microRNA Abundance in Blood and Tissue
Andrea S Bauer (2012)
10.1371/journal.pmed.1000046
A Compendium of Potential Biomarkers of Pancreatic Cancer
H. C. Harsha (2009)
10.6092/1590-8577/3402
MicroRNA expression analyses in preoperative pancreatic juice samples of pancreatic ductal adenocarcinoma.
Yoshihiko Sadakari (2010)
10.1016/S1542-3565(04)00244-7
Screening for pancreatic neoplasia in high-risk individuals: an EUS-based approach.
M. Canto (2004)
10.1038/ng.2416
Breast cancer risk-associated SNPs modulate the affinity of chromatin for FOXA1 and alter gene expression
Richard Cowper-Sal·lari (2012)
10.1007/978-1-4939-8879-2
Pancreatic Cancer
H. Kocher (2010)
Serum markers in patients with resectable pancreatic adenocarcinoma: MIC-1 vs. CA19-9
J Koopmann (2006)
American Association for Cancer Research. clincancerres.aacrjournals.org Downloaded from Published OnlineFirst
Li (2013)
10.1158/1078-0432.CCR-09-3209
Pancreatic Cancer Screening in a Prospective Cohort of High-Risk Patients: A Comprehensive Strategy of Imaging and Genetics
Elizabeth C. Verna (2010)
10.1186/1756-8722-5-13
The emerging role of MIR-146A in the control of hematopoiesis, immune function and cancer
Catherine Labbaye (2012)
10.1126/scitranslmed.3002543
Recurrent GNAS Mutations Define an Unexpected Pathway for Pancreatic Cyst Development
J. Wu (2011)
Clin Cancer Res
10.1002/ijc.26466
Global microRNA expression profiling of microdissected tissues identifies miR-135b as a novel biomarker for pancreatic ductal adenocarcinoma.
J. Munding (2012)
Serum markers in patients with resectable pancreatic adenocarcinoma: MIC-1 vs. CA19-9
KoopmannJ (2006)
MiR1290 and its potential targets are associated with characteristics of estrogen receptor alpha-positive breast cancer
Y Endo (2012)
10.1186/1476-4598-9-169
MicroRNA, hsa-miR-200c, is an independent prognostic factor in pancreatic cancer and its upregulation inhibits pancreatic cancer invasion but increases cell proliferation
Jun Yu (2010)
10.1053/j.gastro.2012.01.005
Frequent detection of pancreatic lesions in asymptomatic high-risk individuals.
M. Canto (2012)
10.1073/pnas.0804549105
Circulating microRNAs as stable blood-based markers for cancer detection
P. S. Mitchell (2008)
10.1158/0008-5472.CAN-09-2979
Loss of FOXA1/2 is essential for the epithelial-to-mesenchymal transition in pancreatic cancer.
Y. Song (2010)
International Consensus Recommendations on themanagement of patients with increased risk for familial pancreatic cancer (The Cancer of the Pancreas Screening (CAPS) Consortium Summit)
MI Canto (2013)
10.1177/000348947108000408
References
(1971)
10.1111/j.2517-6161.1995.tb02031.x
Controlling the False Discovery Rate: a Practical and Powerful Approach to Multiple Testing
Y. Benjamini (1995)
10.1158/0008-5472.CAN-09-2792
miR-146a suppresses invasion of pancreatic cancer cells.
Yiwei Li (2010)
10.3322/canjclin.39.6.399
Cancer statistics.
N Dubrawsky (1989)
10.1038/ajg.2009.276
The Yield of First-Time Endoscopic Ultrasonography in Screening Individuals at a High Risk of Developing Pancreatic Cancer
J. W. Poley (2009)
10.1373/clinchem.2008.109603
Analysis of microRNAs in pancreatic fine-needle aspirates can classify benign and malignant tissues.
A. E. Szafranska (2008)



This paper is referenced by
10.1007/s12032-014-0177-3
Diagnostic and prognostic significance of serum miR-24-3p in HBV-related hepatocellular carcinoma
Fan-long Meng (2014)
10.3978/j.issn.2305-5839.2015.11.03
Plasma miRNA, an emerging biomarker for pancreatic cancer.
Xiazhen Yu (2015)
10.5348/100076Z04DH2018BA
Intraductal papillary mucinous neoplasm’s 100 most significant manuscripts: A bibliometric analysis
Daniel Hughes (2018)
10.3390/molecules19022458
Clinical Application of MicroRNA Testing in Neuroendocrine Tumors of the Gastrointestinal Tract
C. Vicentini (2014)
10.1016/S1499-3872(15)60368-X
miR-215 overexpression distinguishes ampullary carcinomas from pancreatic carcinomas.
Dong ho Choi (2015)
10.2741/4354
Critical role of miRNAs in pancreatic cancer.
Bingya Liu (2015)
10.1007/978-3-0348-0955-9_4
Circulating Blood-Borne microRNAs as Biomarkers in Solid Tumors.
P. Vychytilova-Faltejskova (2015)
10.1159/000487326
A Comprehensive Assessment of the Role of miRNAs as Biomarkers in Gastroenteropancreatic Neuroendocrine Tumors
Anna Malczewska (2018)
10.1016/j.trsl.2018.07.008
Liquid biopsies for management of pancreatic cancer
Mohamadmahdi Samandari (2018)
10.3748/wjg.v26.i19.2305
Pancreatic neuroendocrine tumors: A review of serum biomarkers, staging, and management.
Zuyi Ma (2020)
10.1038/s41598-020-66120-8
Clinical relevance and functional significance of cell-free microRNA-1260b expression profiles in infiltrative myxofibrosarcoma
Takuya Morita (2020)
10.31491/CSRC.2019.03.027
circ-LDLRAD3 regulates cell proliferation, migration and invasion of pancreatic cancer by miR-876-3p/STAT3
Eerdunduleng Eerdunduleng (2019)
10.3748/wjg.v20.i32.11241
Advances in pancreatic cancer research: moving towards early detection.
Xiang-yi He (2014)
10.1016/S1470-2045(15)00186-2
Consensus on biomarkers for neuroendocrine tumour disease.
Kjell Oberg (2015)
10.1016/j.ajpath.2018.10.005
miRNA and Gene Expression in Pancreatic Ductal Adenocarcinoma.
Anteneh A Tesfaye (2019)
10.1002/jcp.25353
Identification of Novel Biomarkers for Pancreatic Cancer Using Integrated Transcriptomics With Functional Pathways Analysis
Xuan Zhang (2016)
10.2174/1389202921666191217095017
Cell-free microRNAs as Non-invasive Diagnostic and Prognostic Bio- markers in Pancreatic Cancer
N. Gablo (2019)
10.1111/brv.12176
microRNAs in breast cancer: regulatory roles governing the hallmarks of cancer.
Jen Nee Goh (2016)
10.1371/journal.pone.0118745
A Novel MiRNA-Based Predictive Model for Biochemical Failure Following Post-Prostatectomy Salvage Radiation Therapy
Erica Hlavin Bell (2015)
10.1155/2018/6292396
Systematic Review and Meta-Analysis of Diagnostic Accuracy of miRNAs in Patients with Pancreatic Cancer
Xiao Sun (2018)
10.7150/jca.38048
Serum miR-1290 and miR-1246 as Potential Diagnostic Biomarkers of Human Pancreatic Cancer
Jia Wei (2020)
10.1097/MPA.0b013e3182a9ad9d
Pancreatitis-Diabetes-Pancreatic Cancer: Summary of an NIDDK-NCI Workshop
D. Andersen (2013)
10.18632/oncotarget.20277
Prognostic value of microRNA expression levels in pancreatic adenocarcinoma: a review of the literature
Patrick Wald (2017)
10.1371/journal.pone.0118220
MicroRNA Markers for the Diagnosis of Pancreatic and Biliary-Tract Cancers
Motohiro Kojima (2015)
Inhibiteurs de cytidine désaminase pour le traitement du cancer du pancréas
Pierre Cordelier (2016)
10.1016/j.beem.2016.01.002
Neuroendocrine tumor biomarkers: From monoanalytes to transcripts and algorithms.
Irvin Mark Modlin (2016)
10.18632/oncotarget.10781
Circulating microRNA profiles in plasma: identification of miR-224 as a novel diagnostic biomarker in hepatocellular carcinoma independent of hepatic function
W. Okajima (2016)
10.1556/650.2017.30708
Keringő mikroRNS-ek az endokrin daganatok diagnosztikájában
Ábel Decmann (2017)
NMR-based metabonomic studies of human pancreatic cancer
Rowland Storey (2016)
10.3892/or.2016.5021
miR‑1246 and miR‑4644 in salivary exosome as potential biomarkers for pancreatobiliary tract cancer.
Tatsuya Machida (2016)
10.18632/oncotarget.9491
Plasma microRNA panels to diagnose pancreatic cancer: Results from a multicenter study
Zhe Cao (2016)
10.2147/TCRM.S154226
The role of miRNAs in the diagnosis, chemoresistance, and prognosis of pancreatic ductal adenocarcinoma
Le Yi Ren (2018)
See more
Semantic Scholar Logo Some data provided by SemanticScholar